Duchenne Muscular Dystrophy (DMD)NCT07821125
Urotherapy Education for Families of Children With Duchenne Muscular Dystrophy
A study testing Urotherapy Education in people with Duchenne Muscular Dystrophy (DMD) and Lower Urinary Tract Symptoms (LUTS), run by Lokman Hekim University at 1 site in Turkey (Türkiye).
Trial summary
This study aims to investigate the effects of urotherapy education provided to families of children with Duchenne muscular dystrophy on parents' knowledge, lifestyle changes, and satisfaction with the education. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Duchenne Muscular Dystrophy (DMD), Lower Urinary Tract Symptoms (LUTS)
- What is being tested?
- Urotherapy Education
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Nov 2026to 20 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Being a parent or caregiver of a child diagnosed with Duchenne muscular dystrophy.
- Volunteering to participate in the study.
- Providing informed consent.
- Being able to participate in the online urotherapy education and complete the study assessments.
Who cannot join
- Not completing the urotherapy education session.
- Not completing the required study assessments.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Lokman Hekim University, Ankara, Ankara
Ankara, Ankara, 06370
Demet Öztürk, Phd, 05068394288, demett.ozturkk@gmail.com
About this study
Official title: Effects of Urotherapy Education Provided to Families of Children With Duchenne Muscular Dystrophy on Knowledge, Lifestyle Changes, and Training Satisfaction
This study aims to investigate the effects of urotherapy education provided to families of children with Duchenne muscular dystrophy on parents' knowledge, lifestyle changes, and satisfaction with the education. Families will receive an online urotherapy education session covering lower urinary tract function, bladder and bowel habits, appropriate toileting behaviors, lifestyle recommendations, and related management strategies. Parents' knowledge and awareness will be assessed before the education, immediately after the education, and two weeks later. Satisfaction with the education will also be evaluated after the session.
Read the detailed description
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder that may also be accompanied by lower urinary tract symptoms. Urotherapy is a conservative, non-pharmacological approach that includes education on bladder and bowel function, appropriate voiding and defecation habits, lifestyle modifications, and strategies for managing lower urinary tract symptoms.
This prospective interventional study will evaluate the effects of an online urotherapy education program provided to families of children with DMD. The education will be delivered remotely in a single session of approximately three hours. Participants will be assessed before the education, immediately after the education, and two weeks later and 2 months after. The study will examine changes in parents' knowledge and awareness of urotherapy-related behaviors and lifestyle practices, as well as their satisfaction with the education provided.
- Being tested
- Urotherapy Education
- Keywords
- Duchenne muscular dystrophy, lower urinary tract symptoms, urotherapy, education
- Medical subject headings
- Muscular Dystrophy, Duchenne, Lower Urinary Tract Symptoms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Urotherapy EducationBehavioural
Participants will receive a single online urotherapy education session lasting approximately three hours. The education will include information about lower urinary tract anatomy and function, lower urinary tract symptoms, bladder and bowel habits, appropriate voiding and defecation postures, scheduled voiding and defecation, fluid intake, lifestyle modifications, pelvic floor muscle awareness, and general strategies for managing lower urinary tract symptoms. Educational materials may include visual materials, videos, and other supporting resources.
| Study group | Role | What they receive |
|---|---|---|
| Urotherapy Education Group | Other | Participants in this arm will receive a single online urotherapy education session lasting approximately three hours. The education will include information on lower urinary tract anatomy and function, bladder and bowel symptoms, appropriate voiding and defecation habits and postures, lifestyle modifications, fluid intake, and strategies for managing lower urinary tract symptoms. Knowledge and awareness will be assessed before the education, immediately after the education, and two weeks later and eight weeks later, and satisfaction with the education will be evaluated after the session. Receives: Behavioral: Urotherapy Education |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Urotherapy Knowledge Level
Parents' knowledge of urotherapy will be assessed using a 10-item knowledge test developed by the researchers based on the educational content. The test consists of five true/false and five multiple-choice questions. Each correct answer is worth 10 points, resulting in a total score ranging from 0 to 100. Higher scores indicate a higher level of knowledge about urotherapy.
Measured: Baseline, two weeks after, 8 weeks after
Secondary outcomes (2)
Change in Urotherapy-Related Lifestyle Behaviors
Urotherapy-related lifestyle behaviors will be assessed using awareness questions developed by the researchers. The questions evaluate voiding frequency, defecation frequency, daily water intake, consumption of tea, coffee, and carbonated beverages, appropriate toileting posture, and implementation of lifestyle recommendations introduced during the urotherapy education. Changes in these behaviors after the education will be evaluated.
Measured: After 2 weeks and 8 weeks
Satisfaction With Urotherapy Education
Satisfaction with the urotherapy education will be assessed using an 8-item satisfaction questionnaire developed by the researchers. Each item is rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score ranges from 8 to 40, with higher scores indicating greater satisfaction with the education.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Dec 2026 (estimated)
- Study completion20 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Duchenne Muscular Dystrophy (DMD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A single-group pretest-posttest design will be used. All participants will receive the same online urotherapy education, with assessments conducted before the education, immediately after the education, and two weeks after the education and 8 weeks after.
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lokman Hekim University
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Demet Öztürk, Lokman Hekim University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07821125
- Sponsor's protocol ID
- 2022/12
- Status last verified
- Sep 2026
- First submitted
- 4 Sep 2026
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No